Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock by Klemcke, Harold G et al.
428  Current Genomics, 2011, 12, 428-442   
  1389-2029/11 $58.00+.00  ©2011 Bentham Science Publishers 
Life or Death? A Physiogenomic Approach to Understand Individual 
Variation in Responses to Hemorrhagic Shock 
Harold G. Klemcke*
,1, Bina Joe
2, Rajiv Rose
1 and Kathy L. Ryan
1 
1U.S. Army Institute of Surgical Research, Fort Sam Houston, TX 78234, USA; 
2Physiological Genomics Laboratory,
 
Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA 
Abstract: Severe hemorrhage due to trauma is a major cause of death throughout the world. It has often been observed 
that some victims are able to withstand hemorrhage better than others. For decades investigators have attempted to 
identify physiological mechanisms that distinguish survivors from nonsurvivors for the purpose of providing more 
informed therapies. As an alternative approach to address this issue, we have initiated a research program to identify 
genes and genetic mechanisms that contribute to this phenotype of survival time after controlled hemorrhage. From 
physiogenomic studies using inbred rat strains, we have demonstrated that this phenotype is a heritable quantitative trait, 
and is therefore a complex trait regulated by multiple genes. Our work continues to identify quantitative trait loci as well 
as potential epigenetic mechanisms that might influence survival time after severe hemorrhage. Our ultimate goal is to 
improve survival to traumatic hemorrhage and attendant shock via regulation of genetic mechanisms and to provide 
knowledge that will lead to genetically-informed personalized treatments. 
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  Throughout the world, traumatic injury is a major cause 
of death and the leading cause of years-of-life lost [1]. 
World-wide, hemorrhage is responsible for 30-40% of all 
traumatic deaths [1] and approximately 50% of battlefield 
deaths [2]. While many combat deaths are so severe that 
even immediate treatment using current medical capabilities 
could not save the victim, ~ 24% of combat deaths could 
potentially be prevented if medical treatment was 
immediately available; 85% of these potentially preventable 
deaths are due to severe hemorrhage [3]. 
  In response to hemorrhage (either alone or combined 
with traumatic injury to tissues), a variety of physiological 
mechanisms are marshaled to maintain blood pressure and 
thereby tissue perfusion for as long as possible. When these 
compensatory mechanisms fail and tissue perfusion is 
diminished to critical levels, a condition of shock exists, 
defined as “an abnormality of the circulatory system that 
results in inadequate organ perfusion and tissue 
oxygenation” [4]. This can subsequently produce cellular 
dysfunction that may become irreversible without adequate 
resuscitation. Finding solutions to the continuing problem of 
severe traumatic hemorrhage and attendant shock is an 
ongoing objective of the U.S. military and many medical 
universities throughout the world, with most research 
focusing on development of procedures to stop bleeding and 
restore tissue perfusion [5-12]. Most such procedures have 
provided some, but not complete, reversal of adverse 
conditions associated with hemorrhagic shock, especially   
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with very severe combat-related injuries. As an alternative 
approach, recent investigations have suggested that 
optimization of the ability of the tissues to withstand 
hemorrhage is critical and that the magnitude of this ability 
differs among individuals, thereby suggesting a genetic 
component. The purpose of this review is to summarize this 
recent work.  
ALTERNATIVE APPROACHES 
  Bellamy and colleagues suggested in 1996 that: “… We 
need a new approach toward managing the rapidly 
exsanguinating casualty. We need to be able to 
pharmacologically induce a state of temporary tolerance to 
ischemia...” [13]. Other investigators stated that “…the key 
to improved care may not involve hemodynamics alone but 
likely requires an understanding of the molecular and 
cellular responses that are triggered by massive blood loss 
and shock. …Mechanisms that may induce tolerance to 
ischemia and cellular hypoxia (e.g., hibernation, ischemic 
preconditioning, and hypothermia) should be explored….” 
[14]. In agreement with these concepts, numerous studies 
have been conducted that seek to improve the ability of the 
organism to withstand the global ischemia of hemorrhagic 
shock when it is not possible to stop bleeding and restore 
normal perfusion (Table 1). Most such approaches have been 
used primarily in animal models, but a few have been either 
used in humans (artificial hibernation, naloxone), or are 
awaiting clinical trials (hypothermia, glutamine; http://clini-
caltrials.gov). Investigation of these and alternative 
compounds is currently an area of very active research. 
SURVIVORS VS NON-SURVIVORS 
  It has been noted for decades, however, that there is 
considerable variability in the ability of patients to survive Physiogenomic Studies of Hemorrhagic Shock  Current Genomics, 2011, Vol. 12, No. 6    429 
traumatic hemorrhage [15]. Indeed, phenotypic variability is 
a commonplace occurrence in the realm of biology [16]. For 
humans, the source of this variability in the ability to survive 
severe hemorrhage is multifactorial and may include 
variation in the nature of the traumatic hemorrhage, the 
biological nature of victims (e.g., age, lifestyle, general 
health, chronic disease states), and the immediacy of trained 
caregivers and hospital facilities. If the innate ability of the 
individual to survive hemorrhage is considered as a 
phenotype of that individual, then it also becomes apparent 
that this phenotype can be influenced by the underlying 
genetic background of the individual. 
  Numerous studies have been conducted to characterize 
and understand the physiological differences between 
individuals that survive hemorrhagic shock and those that do 
not. Shoemaker and colleagues initiated studies as early as 
1970 in attempts to understand the physiological differences 
between survivors and nonsurvivors of hemorrhagic shock 
[17]. Subsequent work by these investigators with trauma 
patients indicated that the physiological measurements most 
different between the two groups were cardiac index, oxygen 
delivery, and tissue oxygen utilization (e.g., [18-20]). This 
differing ability to deliver oxygen and use it at the tissue 
level is reflected in an association between lower blood 
lactate levels and an increased probability of survival [21]. 
Other studies have shown associations between patient 
survival and inflammatory cytokines [22] or heat shock 
proteins [23]. In rat studies, enhanced survival has been 
associated with higher respiration rates, arterial PO2, 
hemoglobin oxygen saturation percentages, blood O2 
content, and blood pH, as well as lower lactate levels [24-
26]. All such measures and observations reflect the above-
noted activation of multiple compensatory systems 
subsequent to severe hemorrhage, and provide clues to 
mechanisms associated with differential survival to 
hemorrhage. However, such clues are often difficult to 
interpret and prioritize importance as they represent the net 
effect of multiple mechanisms.  
DETERMINING CELLULAR MECHANISMS 
  From the above brief review, it is obvious that factors 
contributing to differential survival are numerous and 
diverse in character, involving multiple systems, organs, 
tissues, and cellular pathways. Many different approaches 
could be and have been used in attempts to ascertain which 
cellular factors are both involved and important (e.g., [27 , 
28-34]). Hence, there is a reasonably broad literature that 
indicates potential candidate genes involved in providing 
either: 1) the basal functioning from which each individual 
responds to hemorrhage; or, 2) the multiple and initially 
integrated responses to severe hemorrhage as the organism 
attempts to maintain homeostasis. All such procedures 
involve measurement of gene expression either at the mRNA 
or protein level. However, interpretation of gene expression 
(mRNA, protein, activity) for initial "discovery" procedures 
is confounded by the fact that expression is usually 
dependent on the types of tissue or cells used, and may also 
be dependent on the time of sampling. Therefore, sampling 
of multiple tissues at multiple times is often required to 
obtain an accurate assessment of gene expression. 
POTENTIAL GENETIC INVOLVEMENT 
  So the question becomes, “How should all such gene 
expression data be meaningfully integrated so that 
mechanisms that improve survival to hemorrhagic shock can 
be identified  and ultimately manipulated?” The insightful 
thoughts contained within two salient articles that embodied 
years of research in the areas of cardiovascular function, 
blood pressure regulation, and hypertension provided 
potential answers [35-36]. This work focused our attention 
on the probability that variability in survival time 
(phenotypic variability) could be accounted for by genetic 
variability (polymorphisms), and hence that a genomic 
approach to solving this phenomenon might be both logical 
and appropriate. At the gene sequence level, single 
nucleotide polymorphisms (SNP) represent the smallest and 
Table 1.  Some Alternative Approaches Tested to Improve Survival to Hemorrhagic Shock 
Approach  Representative References  Translated to Clinical Trials or Patient Use for Hemorrhagic Shock 
Artificial Hibernation  [174-176]  Yes 
Hypothermia [177-179]  Yes 
Hydrogen Sulfide  [180-182]  No 
Melatonin [183-185]  No 
-hydroxybutyrate [186-188]  No 
Ethyl Pyruvate  [189-190]  No 
Estradiol [191-193]  No 
Crocetin [194-196]  No 
Glutamine [197-199]  Yes 
Histone deacetylase inhibitors (e.g., valproic 
acid) 
[168-169, 200-201]  No 
Naloxone [202]  Yes 430    Current Genomics, 2011, Vol. 12, No. 6  Klemcke et al. 
most common element of variability accounting for 
phenotypic variability among individuals [37]. Epigenetic 
alterations at the gene level (detailed below) may also 
represent an important and widespread component of inter-
individual variability [38]. While other investigators have 
previously explored gene expression and genetic 
polymorphisms in cells taken from trauma patients [39,40], 
systematic laboratory determination of the genes responsible 
for an organism’s ability to survive hemorrhage have  not 
been previously undertaken.  
  All characteristics of an organism are determined by that 
organism's DNA sequence and the interaction of that DNA 
sequence, transcripts, and proteins with each other and with 
the environment. The multiplicity and complexity of the 
many interacting mechanisms that ultimately lead to a given 
phenotype has been the subject of many recent reviews (e.g., 
[41-45]), and our knowledge in these areas is ever-evolving. 
Complex traits are those that do not exhibit classical 
Mendelian dominant or recessive inheritance associated with 
a single gene [46]. Rather, most depend upon the actions of 
multiple genes. These polygenic traits may be classified as 
either discrete or at least discontinuous [46,47] (i.e., cleft lip 
or palate, [48]) or as quantitative traits that are measured by 
continuous variables such as height and blood pressure [35, 
46,47]. The gene loci or chromosomal regions that control a 
quantitative trait have been called quantitative trait loci 
(QTL), which are often broad chromosomal regions 
containing multiple genes, one or more of which is involved 
in controlling the phenotype of interest [35]. Most QTL span 
very large chromosomal regions (10-30 centimorgans, cM; 
in mice and rats, 1 cM is approximately equal to ~2,000,000 
base pairs or 40 genes per cM). Hence, initial QTL may 
contain hundreds of genes, and subsequently need to be 
better defined [35,36].  
  The complexity of the response to hemorrhage and the 
multitude of factors potentially regulating this response 
suggest the probability that survival time after hemorrhage 
(STaH) may constitute a complex trait, and indeed a 
quantitative trait that demonstrates continuous variation. 
Moreover, if STaH is regulated by genes, then identification 
of these genes and their polymorphisms should ultimately 
provide not only an understanding of variant response 
mechanisms, but also the means to improve survival in 
victims of hemorrhagic shock.  
A PHYSIOGENOMIC APPROACH 
  Strategies for determining the causal relationships 
between genes and complex physiological traits have been 
evolving and improving during the past two decades [49]. 
Indeed, multiple complex traits such as hypertension [35], 
stroke [50], obesity [51], aging [52], and type 2 diabetes [53] 
have received considerable investigatory attention as 
scientists and clinicians attempt to understand and ultimately 
regulate these traits. Having adopted such an approach, one 
may utilize a variety of tools and procedures for which there 
is ample evidence and documentation [54-59]. All such 
procedures are aimed at identifying variability in the 
sequence of nucleotides (polymorphisms) that might lead to 
differences in the amount or activity of proteins for which 
they code. Similarly, our approach is to gain knowledge that 
ultimately will improve patient care by being able to identify 
in each patient genetic and epigenetic markers that will allow 
for better-informed individual treatment. In this, our 
approach is both alternative and complementary to the 
efforts of other investigators seeking to find genetic 
mechanisms associated with enhanced survival to 
hemorrhage (see below). 
  Our physiological genomic approach has initially focused 
on the identification of QTL, and ultimately genetic 
polymorphisms, associated with STaH in inbred rat strains 
(Fig.  1). Additional genomic and molecular biological 
“tools” are being used to supplement the genomic-based 
approach. As these measures (mRNA, protein, and 
physiological characteristics) reflect gene expression, we 
remain mindful of the above-noted caveats in their 
interpretation; i.e., measured levels of such variables may be 
dependent on the time of measurement with reference to the 
hemorrhage, as well as on the site (tissue) of measurement. 
While hemorrhagic shock is accompanied by tissue damage 
that is often severe in trauma patients, we have focused only 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). An integrated physiogenomics approach to identification of genetic polymorphisms and other genetic mechanisms that regulate 
survival time after severe hemorrhagic shock. 
Integrated Approach
Genes regulating survival time
after hemorrhage
QTL Mapping (linkage analysis,
consomic and congenic rat strains)
Physiological 
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Candidate and global 
protein analysis
Candidate and global
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on the hemorrhage aspect of traumatic shock in our initial 
work. Rats are surgically catheterized, and 24 hours later are 
subjected to a severe hemorrhage while conscious and 
unrestrained. This experimental model therefore allows us to 
conduct studies that are minimally confounded by effects of 
anesthetics and analgesics. 
  As an initial attempt to identify genes associated with 
STaH, we tested the hypothesis that survival time after 
controlled hemorrhage is a heritable quantitative trait. To do 
this, we measured this phenotype (STaH) in multiple strains 
of inbred rats; individuals within inbred strains are 
genetically similar. Our data (Fig. 2) demonstrated an 
apparent 8-fold difference in average survival time among 
strains [60]. Dark Agouti (DA) rats had the shortest average 
survival time (40 ± 5 min), whereas Brown Norway/ Medical 
College of Wisconsin (BN/Mcwi) had the longest survival 
time (306 ± 36 min). The percent of animals surviving the 
hemorrhage varied from 0 to 82% across strains (P < 0.001).  
  In this initial study, 55% of the calculated blood volume 
was removed from all rats using a blood volume to body 
weight ratio of 5.83 ml/100g body weight (BW) that was 
based on the average of previously reported blood volumes 
from outbred rats [61-63]. In designing this first study, we 
accepted the fact that this ratio may differ among inbred rat 
strains, and we considered such differences to be one of the 
genomic-associated mechanisms that might be related to 
differences in STaH. We therefore chose five strains for use 
in studies designed to address concerns that blood volumes 
might be different among these inbred rats and to ensure that 
future measurements of survival time reflected the same 
hemorrhagic challenge. The choice of these five strains was 
based on their differences in survival time and on the 
availability of genetic “tools” (i.e., consomic and congenic 
rat strains) for subsequent studies. These inbred strains were: 
BN/Mcwi (the strain with the longest STaH), Fawn Hooded 
Hypertensive (FHH), Dahl Salt Sensitive (SS), Lewis 
(LEW), and DA rats (the strain with the shortest STaH). We 
then measured blood volumes in rats from each inbred strain 
using an Evan’s Blue dye procedure. We found not only that 
blood volumes differed (Fig. 3), but also that this trait had a 
high degree of heritability (h
2 = 0.56) [64].  
  With this information, it appeared quite possible that 
differences in survival times measured in our initial study 
might in part reflect the different blood volumes inherent to 
each strain and therefore differences in percentage of blood 
removed. Hence, we repeated our initial study using the now 
known average normalized blood volumes to calculate the 
amount of blood removal required to achieve a 47% 
reduction in blood volume. We found that, with comparable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Survival time in inbred rat strains to a controlled hemorrhage. Values inside bars indicate the number of rats that lived / total number 
of rats for that strain. Bars represent the mean ± SEM. The vertical dashed line represents 360 min, the maximum observation period at 
which rats were euthanized if still alive (censored data). Rat strains: Brown Norway Medical College of Wisconsin (BN/Mcwi), Dahl Salt-
Sensitive (S), Brown Norway (BN), Outbred Sprague Dawley (Outbred), Copenhagen 2331 (COP), Dahl Salt-Resistant (R), Lewis (Lew), 
Munich Wistar Fromter (MWF), BDIX, Spontaneously Hypertensive (SHR), Noble, Fawn Hooded Hypertensive (FHH), Black agouti (ACI), 
PVG, FISCHER 344 (F344), and Dark Agouti (DA) [33]. Reproduced with permission from Lippincott, Williams, & Wilkins. 432    Current Genomics, 2011, Vol. 12, No. 6  Klemcke et al. 
degrees of hemorrhage, rats from these inbred rat strains 
responded differently (Fig. 4) from the original study. 
Indeed, DA rats (now the longest survivor) lived on the 
average ~3-fold longer than the shortest lived survivor, 
BN/Mcwi [64]. Moreover, STaH appeared to be a heritable 
(h
2 = 0.44) quantitative trait. From this study, we concluded 
that, while the inherent blood volume played a major role in 
determining STaH, other genetic factors were also involved 
in producing this phenotype. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Normalized blood volume in inbred rat strains measured 
using an Evans Blue procedure. Each bar represents the mean ± 
SEM of the number of rats noted in parentheses within bars. Bars 
with different letter superscripts (a, b, c, d) are significantly 
different (P<0.05) [64]. Adapted from Physiological Genomics 43: 
758-765, 2011; “Am Physiol Soc, used with permission”. 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Survival time in inbred rat strains to a controlled 47% 
hemorrhage. Values below bars indicate the number of rats that 
lived / total number of rats for that strain. Bars represent the mean ± 
SEM. Rat strains: Brown Norway Medical College of Wisconsin 
(BN/Mcwi), Dahl Salt-Sensitive (SS), Lewis (Lew), Fawn Hooded 
Hypertensive (FHH), and Dark Agouti (DA). Overall results of 
strain comparisons for survival times (log-rank test) and for 
survival ratios (Chi-Square test) are presented. Bars with different 
letter superscripts (a, b, c, d) are significantly different (P<0.05) 
[64]. Adapted from Physiological Genomics 43:758-765, 2011; 
“Am Physiol Soc, used with permission”. 
  In related attempts to determine genes associated with 
enhanced survival to traumatic hemorrhage, other 
investigators have focused on specific candidate gene 
polymorphisms to determine their association with mortality 
in trauma patients. Such investigations indicate that specific 
polymorphisms associated with mitochondrial Complex 1 
[65] and complement component 2 [66] may be associated 
with increased mortality of trauma victims. Alternatively, a 
polymorphism in a -2 adrenergic receptor (ADBR2: Q27E) 
was associated with enhanced survival after various blunt 
and penetrating injuries [67]. 
COMPLEMENTARY RESEARCH 
  The focus of our short review is hemorrhagic shock 
resulting from injury and rapid exsanguination. Moreover, at 
least initially, our research focus is concerned with the initial 
time interval after injury (0-6 hours) during which 
hemorrhagic shock has the greatest impact on mortality [68]. 
There are, however, other clinical conditions resulting from 
trauma but not specifically related to hemorrhagic shock that 
have received more attention from a genetic and genomic 
approach. The thread that connects this research is the quest 
to understand and ultimately to treat the variability in 
individual responses to these trauma-associated conditions. 
  As noted above, other investigators have begun 
examining the complexity of organismal responses to trauma 
[39-40], and have aggressively focused their efforts on 
understanding inflammatory responses to trauma. A great 
deal of this work has been accomplished via  the 
establishment of the Inflammation and the Host Response to 
Injury consortium, funded as a "glue" grant by the National 
Institute of General Medical Sciences (e.g., [69-72]).  
  Sepsis is a fairly common consequence of severe 
traumatic hemorrhage that results from an altered 
functioning of the immune system [73] that may ultimately 
lead to multiple organ failure [74]. Differences in 
inflammation-related genes associated with differential 
susceptibility to sepsis have been recently reviewed [75,76]. 
Most work to date has focused on polymorphisms of 
candidate genes associated with differing inflammatory 
responses that result in differing individual susceptibilities to 
sepsis.  
  Research into a genetic involvement in variability in 
responses to similar traumatic brain injuries has also been 
conducted for over a decade [77,78]. Much of this genetic 
work has involved polymorphisms of apolipoprotein E [77-
79] but polymorphisms of multiple genes have also come 
under scrutiny [80]. To date, all such physiogenomic-based 
studies have investigated candidate gene polymorphisms 
almost exclusively in human patients [80]. 
  Finally, severe traumatic hemorrhage often makes 
victims more susceptible to acute lung injury (ALI) [81]. 
ALI has been studied at the genetic and genomic levels using 
candidate gene association studies [82] as well as genome 
wide linkage analyses [83]. Although hyperoxic  toxicity 
rather than traumatic injury was used to induce ALI, genetic 
determinants of, and differing susceptibilities to, ALI were 
first indicated in mice [84]. Subsequently, numerous 
candidate genes have been identified that are associated with 
multiple underlying causes of ALI [82, 85]. 
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FUTURE RESEARCH APPROACHES 
  Overall, our investigations conducted using rat models 
provide compelling evidence to suggest that STaH is a 
quantitative trait. The ultimate resolution of genetic factors 
contributing to this trait are expected to be at the level of a 
SNP or a select combination of a group of SNPs (called a 
haplotype block). The challenge that lies ahead is to identify 
loci that control the quantitative trait of STaH. How does one 
proceed? Mere interpretations of comparisons at the 
physiological and biochemical levels of two inbred strains is 
conceptually flawed because of the inability of such 
comparisons to discern whether observed changes at these 
levels are: a) the cause of STaH differences; b) the 
consequence of STaH differences; or, c) due to genetic drift 
(chance selection and fixation of genetic differences 
unrelated to STaH that are forced to occur during inbreeding) 
[86-88]. The solution to this problem is to seek an 
experimental design that avoids the bias of inferences drawn 
by biochemical or physiological functions elicited by the 
action of any given locus (QTL). Such a design–called a 
linkage analysis– uses genetically segregating populations 
derived by breeding two strains of rats and phenotyping 
them for STaH. Such an experimental design allows for 
locating QTLs solely based on their position on the genome 
[35]. The results of a linkage analysis are corroborated by 
substitution mapping using congenic strains [89]. These 
steps are depicted in Fig. (5) and detailed below.  
Stage 1: Genetic Linkage Analysis 
  The first step is to establish statistically significant 
genome-wide evidence for linkage of large regions of the 
genome to STaH. To do so, the two inbred rat strains most 
divergent in STaH (DA females and BN/Mcwi males) will 
be bred to generate a first filial (F1) generation. F1 rats are 
identical, but heterozygous having received one copy of each 
chromosome from each parent. The male F1 will be 
phenotyped and their phenotype compared with the parental 
strains. There are multiple potential outcomes for the F1 
phenotype especially as the number of loci involved with 
STaH increase [90]. If the purpose of the research is to detect 
and to identify one or more major loci that have dominant 
effects on the phenotype of interest (in our case STaH), and 
if F1 rats have an average STaH that is close to that of one of 
the parental strains, then it is most efficient to conduct a 
backcross of F1 individuals to the opposite parental strain to 
produce the N2 generation [90,91]. On the contrary, the F1 
STaH might lie mid-way between that of the two parental 
strains suggesting the absence of dominance of any loci and 
the presence of additive effects. With such results it would 
be more efficient to conduct an intercross of F1 individuals to 
produce an F2 generation [91] . Subsequently, representatives 
(~ 200 rats) of either the N2 or the F2 will be phenotyped 
(STaH measured) and genotyped, and QTL will be 
identified. Genotyping will be conducted using Affymetrix 
GeneChip rat Mapping 10 K Single nucleotide 
polymorphism (SNP) arrays to achieve a genome-wide scan. 
Using this approach, information on chromosomal location, 
the magnitude of the STaH effect, and the mode of 
inheritance of the causative genes can be obtained.  
Stage 2: Substitution Mapping 
  Linkage analysis results in the identification of genomic 
regions
 of approximately 5 to 30 Mb. A genetic interval of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Diagrammatic representation of our approach to identify DNA sequences influencing survival time after severe hemorrhage (STaH) 
in inbred rat strains. Such DNA sequences may include those that are transcribed into mRNA that will be translated into proteins, and 
sequences transcribed as non-coding RNAs such as microRNAs, small interfering RNA, and long non-coding RNA [173]. Dark Agouti 
(DA); Brown Norway/ Medical College of Wisconsin (BN); Fawn Hooded Hypertensive (FHH); Quantitative Trait Loci (QTL).  
Prioritize candidate STaH-specific DNA 
sequences and identify sequence 
variants
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this size typically corresponds
 in humans and rodents to ~50 
to 300  genes [92], which is
  far too many positional 
candidates to begin functional evaluation (i.e., a 
determination of the gene product and its function) of each
 
individual gene. Thus, initial low-resolution linkage studies 
typically establish
  the map location to a resolution that is 
sufficiently precise
  to confirm and define the genomic 
interval. In model systems, this can be done with
 the use of 
consomic strains [93], congenic strains or near-isogenic
 lines 
(e.g., [94-96]). The most popular among these methods that 
is successfully adapted in rodent models is to use congenic 
strains (Fig. 5), which was first described by Snell [97]. The 
basic technique (as detailed by Cowley et al. [98]) involves 
substituting a segment of chromosome from one strain (the 
donor strain) into another strain (the recipient strain). This is 
done by crossing the donor and recipient strains to produce 
F1 animals, and then crossing F1 x recipient (first backcross). 
The offspring of this first backcross are genotyped using tail 
biopsy DNA for markers across a putative QTL-containing 
region of a chromosome. Because chromosomal crossovers 
will occur between the donor and recipient chromosomes in 
meioses of F1 animals, recombinant chromosomes will be 
found in some offspring. This means that an animal with a 
specified donor chromosomal segment can easily be found. 
Such offspring are backcrossed again to the recipient, and 
offspring carrying the specific donor chromosomal segment 
are again selected. This procedure is repeated at least 8 
times. At each backcross, half the unlinked heterozygous loci 
outside the selected (congenic) region become homozygous 
for the recipient allele; that is, the genetic background 
progressively becomes that of the recipient strain. After 
these ~ 8 backcrosses to the recipient strain, rats are 
selectively bred to fix the donor chromosomal segment in the 
homozygous state on the background of the recipient strain, 
producing a congenic strain. The expectation is that the 
introgressed donor segment will alter the phenotype of the 
recipient strain. Because the construction of congenic strains 
relies on recombinations, as long as the phenotypic change is 
traceable, it is second to none as a method for finding genes. 
Occasional disdain toward using congenic strains that is 
found in the literature [99] is not due to the reliability of the 
technique itself, but due to the fact that it is a laborious and 
time consuming procedure. Consomic strains are generated 
the same way as congenic strains except that entire 
chromosomes instead of chromosomal segments are 
substituted. 
  Post-linkage analysis, congenic strains have also been 
constructed and studied for a variety of traits in rat models of 
diseases such as obesity [100], arthritis [101-102], 
hypertension [103-107] insulin resistance [108] and other 
phenotypic traits [109]. We have demonstrated success at 
constructing congenic strains and ‘trapping’ (i.e., 
introgressing a specific chromosome segment from one 
inbred rat strain to the genome of a second inbred rat strain) 
QTL for different disease models, including rheumatoid 
arthritis [101-102], albuminuria [110] and high blood 
pressure [55, 111-113]. Similar to such studies, congenic 
strains will be constructed to ‘trap’ STaH QTLs located 
using DA and BN/Mcwi rats. Alternately, consomic panels 
available for FHH and BN/Mcwi  rats are also useful for 
mapping STaH QTLs (Fig. 5).  
Stage 3: Fine Substitution Mapping 
  The next step, regardless of the consomic or congenic 
approach, is to reduce the size of the critical interval 
containing the QTL as much as possible (Fig. 5). This serves 
to reduce the size of the candidate interval sufficiently such 
that the number of candidate genes is modest and functional 
studies
 can be undertaken. These approaches may be used to 
reduce the
 minimal interval to less than 1 Mb. This will be 
done by backcrossing the parental congenic strain with one 
of the inbred strains. Subsequent intercrosses ensure the 
homozygosity of the congenic substrain [114].  
  In parallel with the conduct of linkage analyses and 
substitution mapping procedures, we will also continuously 
evaluate candidate genes for polymorphisms. The challenge, 
of course, is to choose candidates that have the highest 
probability of being related to our phenotype (STaH). Our 
approach involves multiple means by which to address this 
challenge. First, candidate genes will be identified from the 
literature as those associated with closely related phenotypes 
such as cardiac ischemia, acute lung injury, stroke, traumatic 
brain injury. Second, genes whose mRNA or protein 
expressions are significantly different among inbred rat 
strains divergent in STaH will be evaluated as potential 
candidate genes. Third, using information obtained in steps 1 
and 2, an in-silico analysis will be conducted using 
SNPlotyper [115] to identify polymorphisms associated 
with, or in very close proximity to, those candidate genes. 
Finally, we will screen chosen polymorphic genes for SNPs 
among rats from our survival studies. Such procedures will 
supplement ongoing linkage analyses and have the potential 
for expediting gene discovery. Moreover, they provide 
information that eventually may be used to eliminate 
putative candidate genes after narrowing down loci using 
mapping studies.  
Stage 4: Search for Sequence Variants 
  Minimal QTL intervals (the smallest practical 
chromosomal segment that can be introgressed into congenic 
strains based on naturally occurring meiotic recombinations) 
of <100 kb ‘trapped’ within congenic strains often include
 
more than a single gene [112, 116-117]. The fourth and final 
step is to determine the DNA sequences within the minimal 
QTL interval that are different between BN/Mcwi and DA. 
Advancement in rapid DNA sequencing technologies such as 
the Nextgen sequencing methods [118] is highly favorable 
for obtaining comprehensive data on the candidate variants 
accounting for a particular QTL. Some QTLs result from 
single nucleotide substitutions, while others result
  from 
several variant nucleotides. As a result, each candidate
 
nucleotide variant as well as all combinations of candidate 
nucleotides
  in one or several genes must be identified, 
prioritized, and functionally
 tested. In some cases, it is likely 
that such variants may not reside within protein-coding 
genes. For example, we recently mapped a blood pressure 
QTL to a <81.8 kb congenic segment with no known 
protein-coding genes [119]. At this stage, one could utilize 
complementary evidence resulting from studies measuring 
gene expression (mRNA and protein) to accumulate 
compelling evidence for one gene/non-coding genetic 
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interval. Indeed, the potential importance of non-coding 
RNAs in the overall response to hemorrhagic shock has been 
suggested by changes in non-coding RNAs in various cell 
types in response to ischemia and traumatic brain injury 
[120-124]. Depending on the nature of this superior 
causative candidate gene, other approaches such as 
constructing transgenic rats and/or using technology such as 
silencers of mRNA (RNAi or siRNA) could be used. The 
former has been successfully applied to prove that the Cd36 
gene is a causative factor for insulin resistance in SHR rats 
[125,126]. 
Stage 5: Validation Studies 
  The congenic method has a limitation of not being able to 
resolve regions beyond what is permissible by natural 
recombinations. The extent of resolution achieved can be 
under 100 kb but all variants within this short segment 
remain as candidate genetic determinants of STaH. Even if it 
was possible to narrow the QTL interval further via 
recombination, it is highly unlikely that it will be comprised 
of only a single candidate gene. Rather, additional sequences 
of nucleotides –that may represent other genes– will 
undoubtedly be on either side of the candidate gene of 
interest. Hence, functional studies to validate the importance 
of the candidate gene for our phenotype (STaH) need to be 
conducted. Such studies are most effectively conducted 
using genetically-engineered models such as loss-of-function 
(knock-out) or gene replacement (knock-in) rats. 
Genetically-Engineered Rat Models 
  In recent years, the big impediment of not being able to 
generate targeted gene disruptions or ‘knockouts’ in rats has 
been largely alleviated. The use of homologous 
recombination to modify genes in embryonic stem (ES) cells 
was recently described in rats as a powerful means to 
elucidate gene function [127]. Another, more popular 
method, which was first described in zebrafish [128-130] 
and later in rats [131], is the zinc-finger nuclease (ZFN) 
based targeted gene-disruption. Both of these knock-out 
methods are highly specific to the locus in question [132], 
unlike non-specific gene effects that are to be expected from 
the transgenic approaches wherein a foreign DNA is inserted 
and could potentially result in multiple gene integration sites 
on the genome. Such results would lead to multiple gene-
gene interactions that might obscure the actual function of 
the transferred gene. The feasibility of the ES cell based 
homologous recombination and ZFN-based knockout 
approaches in rats were demonstrated by the construction 
and characterization of p53 (a tumor suppressor) [127] and 
renin [56] gene knockout rats, respectively . 
  Therefore, validation studies of STaH candidate genes 
can be attempted using gene knockout rats. Alternatively, a 
recent report describes the feasibility of a ‘knock-in’ 
approach in rats wherein a select sequence-of-choice is 
introduced into the nuclear genome by homologous 
recombination [133]. This emerging approach will be an 
additional valuable tool for providing proof-of-principle for 
a candidate gene variant to be assessed as a cause for 
observed differences in STaH between DA and BN/Mcwi 
rats. The successful completion of all the above stages 
results in the discovery of a positionally cloned novel gene 
that contributes to STaH.  
What is the Translational Significance? 
  In the context of hemorrhage, any genes contributing to 
increasing STaH that are identified in rats would serve as 
strong candidate genes to evaluate in human victims of 
hemorrhagic shock. Using this population, screening for 
polymorphisms of these genes would determine whether 
there are associations of these genes with survival to 
hemorrhagic shock. Indeed, positional cloning projects for 
complex traits in rats are most rewarding when parallel 
observations of candidate gene associations, or related 
pathways, are reported for the same complex trait in humans. 
For some of the most advanced mapping studies in 
hypertension, such parallel associations have been 
demonstrated in both species. For example, positional 
cloning approaches in rats identified that loss of the Fc 
gamma receptor 3 (Fcgr3) gene is a determinant of 
macrophage overactivity and glomerulonephritis in Wistar 
Kyoto rats [134]. In humans, low copy number of FCGR3B, 
an orthologue of rat Fcgr3, was associated with 
glomerulonephritis in the autoimmune disease systemic 
lupus erythematosus [134,135]. Such parallel observations 
are likely to increase in future years because of the advent of 
dense mapping studies of large human populations (n>1000) 
through genome-wide association studies. In the likelihood 
that association studies are not available for the positionally-
cloned gene for STaH, associations can be sought through 
custom-designed association studies of DNA repositories of 
individuals with pre-recorded phenotypic data on STaH. 
There is at least one such association study reported in the 
field of hypertension. A Disintegrin-like MetalloProteinase 
with Thrombospondin motifs, 16 (Adamts16) was a gene 
positionally prioritized in rats, which was then tested for 
association in hypertensive versus normal subject cohorts 
[119]. ADAMTS16 was indeed significantly associated with 
human hypertension in two independent cohorts [119].  
A POTENTIAL ROLE FOR EPIGENETICS IN 
RESPONSES TO HEMORRHAGIC SHOCK 
  We also recognize that all phenotypic variability among 
individuals, even isogenic individuals, cannot be fully 
explained by classical genetics [136] and environment (Fig. 
6). Phenotypic variability among inbred animals has been 
attributed to a non-genetic and a non-environment “third 
component” [137,138] now known as epigenetic processes 
[139]. More recently, epigenetic processes have been shown 
to result in phenotypic differences among monozygotic twins 
[139-141] and inbred rat strains [142-145]. Numerous 
environmental factors such as maternal care [146], early-life 
stress [147], smoking [148], alcohol [149], air pollutants 
[150], exercise [151] and diet [152] can alter epigenetic 
processes to varying extents at both global and gene 
promoter levels.  
  Defined as heritable changes in gene expression not 
coded by the DNA sequence, major epigenetic mechanisms 
include DNA methylation and post-translational histone 
modifications [153]. They are critical for normal genomic 
functions and act to regulate gene expression. DNA 436    Current Genomics, 2011, Vol. 12, No. 6  Klemcke et al. 
methylation, histone modifications and their interplay are the 
most studied epigenetic mechanisms [154]. Epigenetic 
processes, especially DNA methylation, are more dynamic 
than DNA sequence changes and can be altered by 
environmental and non-environmental stochastic (random) 
events. Further, epigenetic changes may be site specific and 
may vary with tissues or cell types. 
  DNA methylation is the best characterized epigenetic 
process in mammals [155] and entails covalent addition of 
methyl (CH3) groups on cytosines situated in the cytosine-
guanidine dinucleotide [156,157]. DNA methylation 
represses gene transcription while hypomethylation is 
associated with active transcription [158]. DNA methylation 
is essential for normal embryonic development and 
differentiation, genomic imprinting, X-chromosome 
inactivation, genome stability, and tissue specific gene 
expression [159,160]. Histone modifications are another type 
of epigenetic regulation, with acetylation being the best-
understood of the many types of histone modifications 
known to exist [154]. Histone acetylation is a reversible 
modification of select residues in the histones and is 
regulated by histone acetylases and histone deacetylases. 
Histone acetylation can occur globally or at specific 
promoters [154]. Acetylation marks transcriptionally active 
regions while deacetylated histones are found in 
transcriptionally repressed regions.  
  In addition to involvement with a number of human 
diseases [161], epigenetic processes have been demonstrated 
in various animal models in response to local [162-165] and 
global ischemia (e.g., [166]), as well as with the hypoxia that 
attends such conditions [167]. Several studies have now 
shown that alteration of histone acetylation profiles via 
manipulation of histone deacetylase inhibitors improves 
survival to an otherwise lethal hemorrhage [166, 168,169]. 
However, an important question that remains unresolved is 
whether specific epigenetic patterns are associated with 
responses to hemorrhagic shock.  
  We have observed considerable intra-strain variation in 
the STaH in our studies, despite the use of inbred rat strains 
raised in very similar environmental conditions and with 
highly reproducible experimental conditions [64]. We now 
suspect that epigenetic mechanisms may be partly 
responsible for such variability. Hence, both genetic and 
epigenetic mechanisms may be predisposing factors for 
STaH, and our approach (Fig. 1) now includes efforts to 
identify epigenetic mechanisms. Indeed, a similar 
speculation has previously been made based on the extensive 
variability in survival ability to hypoxia in inbred mice 
subjected to whole body hypoxic pre-conditioning [144].  
SUMMARY 
  At this time in the evolution of attempts to first identify, 
and then to regulate, genetic mechanisms associated with 
responses to hemorrhagic shock, we are at an early discovery 
stage. A challenge is to meaningfully integrate the large 
amounts of data that will be forthcoming. The realm of 
systems biology [170] and the rapidly maturing tools of 
bioinformatics should assist. We understand that our 
approach is unlikely to discover all such mechanisms 
associated with STaH, but rather will focus on those genes 
that are different among the inbred rat strains to be studied. 
Other gene combinations and interactions might be operable 
in different inbred rat strains to achieve improved survival. 
However, our ultimate objective is not to determine all genes 
involved, but only ones that are important enough such that 
their manipulation will improve survival to hemorrhagic 
shock.  
  The epigenome represents epigenetic patterns on a 
genome-wide basis [171]. The relationship between the 
genome and the epigenome is as yet unclear. For example, it 
may be possible that the epigenome and its response to 
environmental factors may be determined by the genotype. 
What is clear is that the presence of an epigenome, and the 
fact that different cell types contain different epigenomes, 
adds additional layers of complexity and difficulty to the 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Not all complex phenotypes can be fully explained by genes, environment, or their interactions. Numerous environmental factors 
and stochastic (random) events alter epigenetic processes which may subsequently alter a phenotype. Certain complex phenotypes can also 
influence the epigenome (e.g., ischemic responses). 
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process of associating phenotypes with genotypes for 
complex quantitative traits. Indeed, it is quite likely that both 
genetic and epigenetic variability interact to influence 
phenotypic variability [172]. Advances in high throughput 
screening techniques will facilitate identification of both 
genome-wide and cell-specific epigenomic patterns. An 
improved understanding of the role of both genetics and 
epigenetics in contributing to this complex quantitative trait, 
STaH, will be of importance in the development of novel 
biomarkers for evaluation of varying degrees of 
susceptibility, and for development of future individual-
specific therapeutics (i.e, personalized medicine). 
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